Control BionicsASX:CBL +3.47% PS Ratio is 3.92 as of Jul. 02, 2026, which is 55% above its 10-year median of 2.53. The stock has 4 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Control Bionics ranks worse than 62.36% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Control Bionics's share price is A$0.0745.
Control Bionics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.02. Hence, Control Bionics's PS Ratio for today is 3.92.
The historical rank and industry rank for Control Bionics's PS Ratio or its related term are showing as below:
ASX:CBL'
s PS Ratio Range Over the Past 10 Years
Min: 0.73 Med: 2.53 Max: 11.56
Current: 3.92
During the past 6 years, Control Bionics's highest PS Ratio was 11.56. The lowest was 0.73. And the median was 2.53.
ASX:CBL's PS Ratio is ranked worse than 62.36% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 2.93
vs ASX:CBL: 3.92
Control Bionics Ltd revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Control Bionics was -17.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -21.80% per year.
During the past 6 years, Control Bionics's highest 3-Year average Revenue per Share Growth Rate was -17.00% per year. The lowest was -21.80% per year. And the median was -19.40% per year.
Back to Basics: PS Ratio
Control Bionics (ASX:CBL) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Control Bionics PS Ratio Related Terms
Control Bionics PS Ratio Historical Data
* Premium members only.
The historical data trend for Control Bionics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Control Bionics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Control Bionics PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Control Bionics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Control Bionics's Share Price of today is A$0.0745.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Control Bionics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Control Bionics (ASX:CBL) has a PS Ratio of 3.92 as of Jul. 02, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Control Bionics and its competitors. This is 55% above median its historical median of 2.53. Over the past decade, Control Bionics' PS Ratio has ranged from 0.73 to 11.56. According to the industry distribution chart, Control Bionics ranks #502 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 62.4%.
Is Control Bionics' PS Ratio too high?
Control Bionics' current PS Ratio of 3.92 is 55% above median its 10-year median of 2.53. Over the past 10 years, this metric has ranged from a low of 0.73 to a high of 11.56. The Medical Devices & Instruments industry median PS Ratio is 2.93. Control Bionics' value of 3.92 is 33.8% above this industry median. Based on the distribution chart, Control Bionics ranks #502 out of 805 companies in the Medical Devices & Instruments industry, which is below the industry midpoint.
How does Control Bionics' PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Control Bionics ranks #502 out of 805 companies for PS Ratio. This places Control Bionics in the lower half of its industry. The industry median PS Ratio is 2.93. Control Bionics' value of 3.92 is 33.8% above this benchmark. Historically, Control Bionics' own PS Ratio has ranged from 0.73 to 11.56 over the past decade. While the company's 10-year median is 2.53 vs. the industry median of 2.93, Control Bionics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.93, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Control Bionics's current PS Ratio of 3.92 is 33.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Control Bionics and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Control Bionics's current PS Ratio is 3.92, which is 55% above median its own 10-year median of 2.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.07 — trading 148.3% above its estimated fair value. The current PS Ratio is 3.92, which is 55% above median its 10-year median of 2.53 and 33.8% above the Medical Devices & Instruments industry median of 2.93. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current PS Ratio is 3.92 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CBL has been successfully added to your 